Clonal strain persistence of <em>Candida albicans</em> isolates from Chronic Mucocutaneous Candidiasis patients by Moorhouse AJ et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Moorhouse AJ, Renisson C, Raza M, Lilic D, Gow NAR. Clonal strain 
persistence of Candida albicans isolates from Chronic Mucocutaneous 
Candidiasis patients. PLoS One 2016, 11(2), e0145888. 
 
 
Copyright: 
© 2016 Moorhouse et al. This is an open access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited. 
DOI link to article: 
http://dx.doi.org/10.1371/journal.pone.014588 
Date deposited:   
14/03/2016 
RESEARCH ARTICLE
Clonal Strain Persistence of Candida albicans
Isolates from Chronic Mucocutaneous
Candidiasis Patients
Alexander J. Moorhouse1*, Claire Rennison2, Muhammad Raza2, Desa Lilic2, Neil A.
R. Gow1*
1 Aberdeen Fungal Group, School of Medical Sciences, Institute of Medical Sciences, University of
Aberdeen, Aberdeen, United Kingdom, 2 Institute of Cellular Medicine, Faculty of Medical Sciences,
Newcastle University, Newcastle upon Tyne, United Kingdom
* n.gow@abdn.ac.uk
Abstract
Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency disorder charac-
terised by susceptibility to chronic Candida and fungal dermatophyte infections of the skin,
nails and mucous membranes. Molecular epidemiology studies of CMC infection are limited
in number and scope and it is not clear whether single or multiple strains inducing CMC per-
sist stably or are exchanged and replaced. We subjected 42 C. albicans individual single
colony isolates from 6 unrelated CMC patients to multilocus sequence typing (MLST). Multi-
ple colonies were typed from swabs taken from multiple body sites across multiple time
points over a 17-month period. Among isolates from each individual patient, our data show
clonal and persistent diploid sequence types (DSTs) that were stable over time, identical
between multiple infection sites and exhibit azole resistant phenotypes. No shared origin or
common source of infection was identified among isolates from these patients. Additionally,
we performed C. albicansMLST SNP genotype frequency analysis to identify signatures of
past loss of heterozygosity (LOH) events among persistent and azole resistant isolates
retrieved from patients with autoimmune disorders including CMC.
Introduction
Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency disorder charac-
terised by susceptibility to Candida spp. infection of the skin, nails and mucous membranes. It
manifests separately to vulvovaginal candidiasis and rarely as invasive candidiasis. Generally
presenting as chronic localised lesions, CMC persists due to isolated primary immune defects
or secondary to predisposing immune compromising conditions such as HIV. It can also pres-
ent as a heterogeneous disorder such as autoimmune polyendocrinopathy candidiasis ectoder-
mal dystrophy (APECED), as a multisystem syndrome with hyper immunoglobin E syndrome
(HEIS) or hypothyroidism, and can be complicated by additional autoimmune conditions such
as inflammatory bowel disease (IBD) [1–3].
In healthy individuals, immunological surveillance of potential invasive microorganisms
involves immune recognition of the pathogen and activation of innate and adaptive immune
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responses [4]. In CMC patients, defects affecting innate (dectin-1, CARD9, IL12RB1) and
adaptive (interleukin (IL)17-F, IL17 receptor, STAT1, STAT3) immunity disrupt the protective
mucosal Th-17 pathway preventing effective response to superficial fungal infections [1]. The
largest aetiological class of CMC is caused by a dominant mutation in STAT1 [5,6] such as
gain of function at coil-coiled domain [3] and DNA binding domain [1,7]. A premature stop
mutation in the dectin-1 gene is also a known risk factor for CMC with allele prevalence of
3–8% in healthy populations [8]. Detailed discussion of CMC aetiology benefits from several
informative reviews [1,9,10]. Understanding the molecular epidemiology of Candida spp. in
chronic fungal infection is vital to developing improved preventative and therapeutic treat-
ments and strategies to alleviate suffering. DNAmarker typing strategies for C. albicans isolates
have been explored extensively [11–13], and multilocus sequence typing (MLST) is now a stan-
dard measure of population structure for the major pathogenic Candida spp. [14–20]. Notably,
MLST studies of non-C. albicans, Candida spp. reveals a more marked clonality among molec-
ular types with a highly stable population structure in C. dubliniensis [21–23], C. glabrata
[24,25], and C. tropicalis [26,27]—commonly encountered Candida spp. after C. albicans.
The accepted model of C. albicans population structure is one of predominant clonality
with rare recombination events as a result of cryptic mating strategies generating new highly
differential strain types, but more often, incremental mutation events such as point mutations
and loss of heterozygosity (LOH) responsible for low level, within population, genetic diversity
and adaptation [28–31]. The prevailing stability of C. albicans populations is observed most
pertinently in studies using isolates taken at serial time points, which also provides opportunity
to observe the emergence of antifungal drug resistant phenotypes and associated mutational
changes when they do arise [32–34].
Molecular epidemiology studies have targeted Candida spp. population structure within
nosocomial infections [35,36], among drug resistant isolates [37,38], and specific infection
types [39–42], often seeking to observe the extent of particular Candida spp, clades and strain
type enrichment within cohorts [43,44]. As yet few studies have addressed these epidemiologi-
cal patterns among isolates causative of CMC, a condition in which chronic infections may
persist beyond several years [45,46]. Two previous studies investigating the molecular epidemi-
ology of CMC patients demonstrate the emergence of azole resistant C. albicans DSTs causative
of infection. McMannus et al. conducted serial swab sampling and identified 18 C. albicans
DSTs from 14 CMC patients. Multiple DSTs identified from individual patients were as a result
of micro-variation rather than strain replacement or recombination. They also demonstrated
acquisition of azole resistance over time as a result of mutations in TAC1 and ERG11 [46]. Sii-
kala et al. [45] also conducted serial sampling of 9 CMC patients and observe similarly persis-
tent infection along with mutations in TAC1 and ERG11 genes. Interestingly these mutations
did not always confer increased resistance to azoles and were occasionally transient within
infection populations. Jacobsen et al. [47] identified a reduced number of DSTs among non-
serial oral isolates with autoimmune conditions including Lichen Planus, Sjorgen’s syndrome
and mucous membrane pemphigoid when compared with healthy volunteers and VVC
patients. Here we report clonal and persistent DSTs in CMC patients over a 17 month period,
and evidence of loss of heterozygosity in persistent colonising strains.
Materials and Methods
Patient Recruitment, Background and Swabbing
More than 20 patients with chronic mucocutaneous candidiasis (CMC) were followed in our
regional “Candidiasis” clinics. We report only on six unrelated patients, four females (P1, 2, 4
and 6) and two males (P3 and 5) for whom we found persistent positive cultures. Swabs were
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taken from infected sites (mouth, genitals, skin) for diagnostic culture and sensitivity testing to
confirm Candida presence. Patients P1-P5 had a primary immune deficiency (PID) manifest-
ing as CMC. Patient P6 had secondary oral candidiasis as a consequence of using steroid inhal-
ers for severe asthma. We previously assessed all PID CMC patients by whole exome
sequencing as part of a separate study [3] in which we identified gain-of-function STAT1
mutations in P1, P3 and P5, no mutation was identified in P4 or P6. GOF-STAT1 CMC
patients and P6 had disease onset in early childhood/adolescence while P4 who had a candida
granuloma of the soft palate and has since developed squamous cancer of the same area first
presented at 50 years of age. PID CMC patients were followed for at least 5 years in this clinic,
during which time all of them were on antifungal oral treatments. Antifungals were selected
based on sensitivities and were either azoles (fluconazole and itraconazole) or amphotericin
suspension 100 mg/ml (produced in our local hospital Pharmacy), diluted 1:10 before taking
into mouth, swirled and swallowed 4x daily. (See Table 1).
Multiple colonies were typed from swabs taken over a 17 month period. Patients 1 and 3
were swabbed 4 times, patient 6 was swabbed twice and patients 2, 4 and 5 were swabbed once.
Oral swabs were taken at all sampling time points, swabs of the groin and buttocks were taken
for the penultimate time point of patient 3 (Table 1 and S1 Fig).
Isolation and species identification
Patient samples were plated and purified on Sabouraud dextrose (Sabdex) agar plates contain-
ing 1% mycological peptone (w/v), 4% (w/v) glucose and 2% (w/v) agar and CAN2 agar (Bio-
merieux) to detect the presence of mixed isolates. Isolates of yeasts were also inoculated into
Sabdex broth. Species identification was carried out using MALDI TOF mass spectrometry. All
swabs were taken for routine diagnostics purposes. Ethical approval was obtained under the
Newcastle Autoimmune Inflammatory Rheumatic Disease Research Biobank (NAIRB) Ref No
NAIRB-DL-01 dx obtained from the Southwest 3 Research Ethics Committee (Ref. 10/H0106/
30) to perform research on samples collected as part of the NAIRB by researchers based at
Newcastle University.
Antifungal susceptibility testing
Minimum inhibitory concentrations were determined by broth micro-dilution testing using a
modification of the CLSI (formerly NCCLS) guidelines M27-A2 [48]. Drug concentrations ran-
ged from 0.032 mg/L to 16 mg/L for caspofungin and a non-liposomal amphotericin B suspen-
sion, and 0.13 mg/L to 64 mg/L for fluconazole and voriconazole. Each drug was serially
diluted with sterile water to 50 μL in flat bottomed 96 well plates. Cultures were grown in NGY
medium (0.1% (w/v) neopeptone, 0.4% (w/v) glucose, 0.1% (w/v) yeast extract) for 12 h at
30°C to exponential phase and 20 μL transferred to 11 mL RPMI inoculation medium (2x
RPMI-1640, 2% (w/v) glucose, buffered to pH 7.0 with MOPS). Aliquots of 50 μL inocula in
RPMI were added to drug plates (total volume 100 μL), incubated for 24 h at 37°C and analysed
using VERSAmax microplate reader at 405 nm. Each of 42 sequenced colonies were assayed in
triplicate, and MIC90 and MIC50 values reported.
Genomic DNA extraction and sequencing
Genomic DNA was extracted from yeast grown from single colonies in overnight YPD broth
cultures (1% yeast extract, 2% bacto-peptone and 1% glucose). Pelleted cultures were subject to
mechanical lysis in 2 mL Eppendorf tubes with 200 μl extraction buffer (100mM Tris-HCl [pH
8.0] containing 2% Triton X-100, 1% sodium dodecyl sulfate, and 1 mM EDTA), 200 μl 1:1
(vol/vol) phenol chloroform and 0.3g of acid washed glass beads (0.45 to 0.52 mm in diameter)
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using a bead beater. Addition of 200 μL TE (1 mM EDTA, 10 mM Tris-HCl, pH 8.0) preceded
phase separation by centrifugation and ethanol precipitation of DNA containing upper phase,
as previously described [18]. For each single colony isolate the internal region of seven house-
keeping genes were amplified using seven pairs of primers (S1 Table) in separate PCR reactions
with a first cycle of denaturation for 2 min at 94°C, followed by 25 cycles of denaturation at
94°C for 1 min, annealing at 52°C for 1 min, elongation at 72°C for 1 min, and a final extension
step of 10 min at 72°C. PCR reactions were performed in 20 μl volumes using high-fidelity
DNA polymerase (Finnzymes Phusion F-530L), with thermal cycler conditions as advised by
the manufacturer and as previously described [16]. Aliquots of 5 μl of PCR products were run
on agarose gels to confirm successful generation of products at expected sizes and 5 μl aliquots
were purified using Mag-Bind E-Z magnetic beads as per manufacturer’s instructions. Chain-
terminating dideoxynucleotide Sanger sequencing reactions were prepared from purified PCR
products separately for forward and reverse strands and precipitated with addition of 15 μl
sterile H2O to prevent dye blobs, 50 μl 3 M NaOAC (pH 5.2) followed by 70% ethanol rinse as
previously described [15,49]. PCR products containing purified and dried sequencing reactions
were sent to the University of Oxford, Department of Zoology and sequenced on ABI 3730
instruments. DNA sequence results were analysed and SNPs determined using DNASTAR
Table 1. Patient clinical data. Flucon = fluconazole, itracon = itraconazole, amph sus = amphotericin suspension (10 mg/ml swirl and swallow 4x daily). All
swabs were taken for routine Dg purposes. Ethical approval was obtained under the Newcastle Autoimmune Inflammatory Rheumatic Disease Research Bio-
bank (NAIRB) Ref No NAIRB-DL-01 dx obtained from the Southwest 3 Research Ethics Committee (Ref. 10/H0106/30) to perform research on samples col-
lected as part of the NAIRB by researchers based at Newcastle University. Pts 1–5 had primary CMC; whole exome sequencing confirmed gain-of-function
STAT1mutations in 3 while no mutation was identified in 2 patients; P4 had candida granuloma of soft palate. P6 had 2oCMC due to steroid inhalers
(asthma). Swabs were processed in the Department of Microbiology, Newcastle upon Tyne Hospitals NHS Trust (NUTH): Mohammad Raza, Consultant
Microbiologist (Muhammad.Raza@nuth.nhs.uk) and Claire Rennison, Senior BMS (now retired).
Pt
No
M/
F
age Diagnosis onset of CMC Swab date Candida spp. Identified Prescribed
1 F 64 1oCMC (GOF-STAT1) adolescence 14/11/
2011
C. albicans + C.
nivariensis
Flucon 100 mg/d
16/04/
2012
C. albicans Itracon 100 mg/d
09/07/
2012
C. albicans Flucon 100 mg/d
14/01/
2013
C. albicans Flucon 100 mg/d
2 F 42 1oCMC (GOF-STAT1) adolescence 13/02/
2012
C. albicans Flucon 100 mg/d
3 M 43 1oCMC (GOF-STAT1) early
childhood
09/07/
2012
C. albicans Flucon 100 mg/d
10/09/
2012
C. albicans Itracon 100 mg/d
12/11/
2012
C. albicans Itracon 100 mg/d
13/01/
2014
C. albicans Itracon 100 mg/d + amph sus 10 mg/ml x4/
d
4 F 61 1oCMC (granuloma) 10 yrs ago 13/02/
2012
C. albicans Flucon 100 mg/d;7 days each month
5 M 30 1oCMC (GOF-STAT1) early
childhood
14/05/
2012
C. albicans Flucon 100 mg/d
6 F 43 2o CMC (steroid
inhalers)
8yrs ago 12/11/
2012
C. albicans Itracon 100 mg/d
08/03/
2013
C. albicans amph sus 10 mg/ml x4/d
doi:10.1371/journal.pone.0145888.t001
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Lasergene SeqMan Pro software. Strain types were further confirmed by subsequent re-
sequencing using genomic DNA freshly prepared from cultures grown from -80°C glycerol
strain stocks. DSTs were submitted to the C. albicansMLST central curation database http://
pubmlst.org/calbicans/.
Phylogenetic Analysis
Sequence data at previously identified C. albicansMLST SNP positions were extracted from
our data and concatenated for multiple sequence alignment using Clustal Omega and visual-
ised in MATLAB R2012a. Tree building was carried out with the Unweighted Pair Group
Method with Arithmetic Mean (UPGMA) and visualised using FigTree v1.4.0. Splits phyloge-
nies were prepared in SplitsTree4 v4.13.1. eBurst analysis was performed with eBURSTv3 [50].
(S2 and S3 Figs).
Datasets
A non-redundant dataset of 2867 isolates (Dataset A) was prepared from the centrally curated
MLST C. albicans database as at December 2014 (This database is presently in the process of
migrating from http://calbicans.mlst.net/ to http://pubmlst.org/calbicans/); DST entries were
not included if they were a repetition of the same DST from the same patient unless they
occurred at a separate body site. Further datasets were chosen and constructed from the in
house database of isolates; a reference that has been used to compile and update the online
curated database since its inception. Dataset B: 245 individual isolates of various carriage types
(9 VVC, 77 commensal, 13 candidaemia, 5 sepsis, 38 candiduria and 103 isolates of unspecified
origin), Dataset C: the present data from 42 sequenced colonies from 6 CMC patients, Dataset
D: 36 sextuple sequenced colonies from 6 VVC patients, Dataset E: 24 sextuple sequenced colo-
nies from 4 autoimmune patients with Lichen Planus, Sjogren’s syndrome, mucous membrane
pemphigoid and Lichen Planus respectively, Dataset F: 34 individual isolates from blood
stream infection, Dataset G: 36 sextuple sequenced colonies of oral origin from 6 students.
These datasets were chosen as several series of isolates present in the database as blocks of con-
secutive isolates submitted as discrete collections that have formed part of previously published
MLST work [30,47,51]. (S4 Fig).
SNP frequency distribution
At all SNP positions across MLST sequences, implementing the IUPAC ambiguity nomencla-
ture for heterozygous SNPs, the frequency of each SNP genotype were calculated for Dataset A
and the frequency distribution matrix was used to prepare normalised frequency distribution
matrices of the 6 further datasets (B-G). Further data reduction was performed by tallying
within non-overlapping 10% ranges and multiplying these counts by the range upper bound
value to produce a normalised frequency distribution (NFD) of normalised frequency presence
(NFP), and absence (NFA) in respect of heterozygous (NFPhet, NFAhet) and homozygous
(NFPhom and NFAhom) classes of SNPs. (see also S5 and S6 Figs).
Results
MLST analysis was performed on 42 C. albicans isolates from 6 CMC patients collected over a
period of 17 months. All isolates retrieved from the same patient had the same DST and no
LOH, point mutations or larger scale genetic differences were observed between colonies
obtained from the same patient. Of the 6 DSTs observed, only one (DST 392) had been previ-
ously reported. These data show C. albicans DSTs persisting across time, between different
Persistent and Clonal;Candida albicans in CMC Patients
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anatomical sites as identical DSTs mutually exclusive for each patient in this cohort (Table 2
and S2 Fig).
Phylogenetic analysis
Phylogenetic neighbour net analysis of DST profiles together with multiple sequence alignment
and UPGMA tree of concatenated SNP positions demonstrated the distinct genetic back-
grounds of these isolates. Clade membership and eBurst analysis highlighted 4 identical geno-
types (MP1b, ZWF1b, AAT1a, AAC1) for DST 392 (P4) and DST 2130 (P6) in clade 4, and 4
identical genotypes (ADP1a,MP1b, SYA1, ZWF1b) for DST 2125 (P2) and DST 2129 (P5) in
clade 2 with both pairs of DSTs identical at a single genotype (MP1b). Together these genetic
divisions and groupings strongly confirm independent origins for these isolates with no shared
source of infection for these patients (Table 2, Fig 1 and S3 Fig).
Susceptibility to antifungal drugs
In general, few changes in drug resistance profiles of isolates were noted over the time course
of the study. Most isolates were resistant to both azoles tested from the start of the study period
with MIC values above published breakpoints. The MIC testing revealed similar susceptibility
profiles within a doubling dilution range across multiple isolates from the same swab site and
across multiple swabs at multiple body sites and time points with the exception of two sets of
voriconazole values. A fourfold increase was recoded in voriconazole MIC for P1 and a fourfold
decrease in voriconazole MIC50 occurred between the penultimate and final swab for P3 (data
not shown), the MIC90 values for these isolates remained stable across all swabs for the
patients. Overall these susceptibility data show MIC values for strains of a consistent and rela-
tively highly resistant phenotype with no notable acquisition of increased resistance during sus-
tained chronic carriage over the study period (Table 2).
SNP frequency distribution
To assess the distribution of SNPs across MLST sequences, SNP genotype frequencies were com-
puted for a non-redundant dataset of 2867 isolates taken from the C. albicansMLST database
(Dataset A), and used as a normalising dataset for 6 further datasets with distinct epidemiological
characteristics (Datasets B-G), including 6 individual DSTs identified herein (Dataset C).
Patterns of SNP frequencies for datasets B-G normalised against Dataset A were visualised in
NFD plots to identify hotspots of frequency differences (Fig 2 and S5 Fig). Of particular interest
were increased heterozygous normalised frequency absence (hetNFA) accompanied by increased
homozygous normalised frequency presence (homNFP), as these SNPs are indicative of LOH
events. Interestingly, Dataset C and Dataset E, both derived from isolates obtained from patients
with autoimmune conditions, displayed the most pronounced elevated hetNFA and homNFP
(Fig 2) resulting in the most negative LOHscore of these datasets (S2 Table). Conversely, isolates
obtained from patients with oral and vaginal carriage (Dataset D and Dataset G respectively)
exhibit levels of greater heterozygosity, while those of blood stream origin and those of a range of
clinical origins (Fig 2, S5 and S6 Figs) exhibited a more balanced distribution (Fig 2 and S5 and
S6 Figs). We conclude therefore that these isolates were genetically stable and consistent across
different body sites, although a number of LOH events had occurred in the past.
Discussion
The underlying CMC condition promotes susceptibility to Candida carriage and infection and
we wished to determine whether such patients commonly exchanged Candida isolates or were
Persistent and Clonal;Candida albicans in CMC Patients
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subject to serial colonisation. We therefore sequenced 42 C. albicans colonies for MLST from 6
unrelated CMC patients treated at the same hospital, and multiple colonies were typed from
Fig 1. Multiple sequence alignment of concatenated SNPS of DSTs from 6 CMC patients.Multiple sequence alignment of C. albicans MLST
concatenated SNPs for the 6 DSTs. Blue and green colours are homozygous SNPs, yellow, orange, red, pink and brown are heterozygous SNPs, the
boundaries of the 7 sequenced regions are indicated at the x axis. SplitsTree phylogram of the DSTs profiles appears at the y axis.
doi:10.1371/journal.pone.0145888.g001
Fig 2. Normalised frequency distribution (NFD) of 6 comparator datasets. NFD heat-map of frequency differences for six datasets (B-G) normalised
against a non-redundant dataset of 2867 isolates curated at the central C. albicans database (Dataset A).
doi:10.1371/journal.pone.0145888.g002
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swabs taken from multiple body sites across multiple time points over a 17 month period
(Table 1 and S1 Fig). A single stable DST was identified for all isolates of each individual
patient and no patient yielded isolates with the same DST. These data demonstrate clonal and
persistent DSTs, stable over time and identical between multiple infection sites with no shared
origin or common source of infection for isolates from these patients. Isolates exhibited ele-
vated azole resistance but no acquisition of resistance was notable within serial isolates from
individual patients. However, changes in susceptibility for voriconazole observed at MIC50 but
not MIC90 among isolates from patients 1 and 3 hint towards the potential presence of differ-
entiated sub-populations genetically indistinguishable through MLST but that may harbour
mutations conferring differences in azole resistance, these do not strongly represent an
acquired resistance (Table 2). Additionally, we investigated the landscape of MLST genotypes
to highlight differential frequency patterning of homozygous and heterozygous SNPs, these
data suggest increased levels of past LOH events for persistent and azole resistant colonisers of
patients with autoimmune disorders (Fig 2).
The general stability and persistence of C. albicans populations has been highlighted previ-
ously in MLST studies using isolates taken at serial time points in a range of clinical settings
[32–34]. The few MLST studies of isolates causative of CMC have taken this approach and
have observed over time occasional MLST micro-variations and associated mutations at drug
resistant loci conferring acquired azole drug resistant phenotypes [45,46]. Azoles, are the larg-
est family of antifungal drugs and are popular due to their safe oral profiles, yet there are a
number of mechanisms underlying antifungal resistance to azoles [52–57]. Our data identifies
existing elevated azole resistance within persistent and clonal colonisers of CMC patients and
is congruent with previous studies of CMC using MLST.
Genetic diversity among C. albicans populations can increase through rare recombination
events during cryptic mating and as a result of associated concerted chromosome loss following
transient aneuploidy [58,59]. However, more frequently genetic variation is driven within pop-
ulations by LOH [28–31]. MLST consistently identifies LOH rather than strain replacement or
larger scale micro-evolutionary changes as driving the generation of new strain types [30–34].
Recent genome wide studies have highlighted the importance of LOH in the genetic plasticity
of C. albicans, using lab strains to dissect the role of abiotic stressors to induced LOH [29].
Indeed LOH plays a key role along with SNP and aneuploidy variations in the evolution of
antifungal resistance among clinical isolates [31], and is coupled with mutations at several
mediators of azole resistance including TAC1, CDR1/2, ERG11 andMRR1(MDR) [60,52]. Spe-
cifically these molecular mechanisms are the origin of acquired azole resistance among
APECED CMC patients in two separate studies that identify MLST LOHmutations along with
ERG11 and TAC1 derived overexpression of CDR1/2 [45,46].
It is well recognised that azole resistance develops with long-term use and is often seen in
CMC patients who are on anti-fungal treatment for life. Patients with the PID CMC have an
underlying genetic immune defect and are very rare, the incidence estimated to be 1:100000.
To date, less than 230 patients with GOF-STAT1 mutations have been reported world-wide
(Anne Puel, personal communication, manuscript in preparation). As the mutation was identi-
fied only recently [3], there is very little longitudinal data, and no data regarding Candida spp.
strains and sensitivity in these patients. We report no consistent changes in MIC, but observe
that MICs for azoles of most isolates were above the reported breakpoints suggesting they were
already resistant at the beginning of the period of survey. Some minor changes in voriconazole
were noted; in one case a small increase in MIC was seen whilst in another a decrease was
observed. We conclude that no marked changes in antifungal drug sensitivity occurred over
the 17 months of the survey.
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To our knowledge, analysis of SNP frequencies reported here has not been applied previ-
ously to Candida spp. MLST data in this way. We have developed and implemented a novel
and scalable analytical strategy that highlights the potential for MLST data to identify hall-
marks of past LOH events from large scale MLST datasets. Interestingly these data suggest indi-
cators of elevated levels of past LOH events are found among C. albicans isolates from CMC
and autoimmune patients in comparison with oral, vaginal and blood stream carriage. Further
studies implementing similar analyses with larger datasets may find these signatures of LOH to
be synonymous with the increased azole resistance prevalent among autoimmune infection
types.
Conclusions
MLST studies of Candida spp. have targeted specific clinical groupings such as nosocomial
infections [35,36], periodontitis [40], recurrent bloodstream infection [41,42], cystic fibrosis
[39] and genital candidiasis [44]. Although C. albicansMLST studies have repeatedly reported
clade 1 isolates as the most commonly encountered clade and one associated with an increased
ability to evolve and to cause infection, repeated attempts to draw further clade associations
with clinical classes of infection and with virulence properties have been unsuccessful [43,61].
Similarly, although some geographical enrichment for C. albicans clades has been observed,
MLST is limited in its ability to describe an in-depth evolutionary history of C. albicans geo-
graphic population structure [30,62–64]. This is partly because MLST clades consider only a
few hundred mutations in a reductive manner and use phylogenies that ignore the potentially
informative properties of mutation frequency dynamics within and between populations. C.
albicans exhibits largely clonal populations yet is capable of large scale genetic plasticity that
can rapidly confer selective advantages such as resistance phenotypes. Population distribution
analyses for C. albicans is also made more challenging in an era where individuals commonly
travel internationally and may acquire strains that are not normally indigenous.
Our data demonstrates the frequency distribution of SNPs among C. albicansMLST data-
sets can provide useful biomarkers such as indicators of lost heterozygosity as a proxy for azole
resistance. We detect this signal among isolates colonising CMC patients and suggest this is as
a hallmark of selection for resistance in the absence of functional mucosal immunity. Similarly,
genetic signatures of conserved heterozygosity may be evinced among commensal isolates of
oral, vaginal and GI mucosae where mating and recombination may be more frequent. Using
these approaches to molecular epidemiology of C. albicans isolates may provide improved
methods to distinguish between clinical and geographical cohorts beyond using clades alone.
Future studies implementing higher throughput genome wide sequencing, together with more
sophisticated models for population dynamics of medically relevant yeasts [65–67], will
improve our understanding of the population dynamics of fungal infection in diverse epidemi-
ological arrangements and inform our approach to preventative and therapeutic treatments
and strategies.
Supporting Information
S1 Fig. Sampling Time Line. A time line of sampling for 42 C. albicans isolates from 6 CMC
patients. Patient number, number of isolates and isolate source are indicated in black, month
of sampling appears in blue, red line break indicates turn of the year.
(TIF)
S2 Fig. SplitsTree of DST profiles from 6 CMC patients. Distance annotations appear on
branches, MLST clades memberships appear at tips for single DSTs, blue and yellow ovals
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indicate clade 2 and clade 4 isolates respectively.
(TIF)
S3 Fig. Alignment and UPGMA phylogeny.Multiple sequence alignment of known MLST
SNP base positions from the 6 DSTs from the 6 CMC patients, and UPGMA phylogeny con-
structed from the same alignment.
(TIF)
S4 Fig. Dataset Summary statistics. Clade and genotype membership for Dataset A and sum-
mary ratios for datasets B-G (lower panel).
(TIF)
S5 Fig. Normalised Frequency Distribution (NFD) Plots. Individual DST NFD plots of iso-
lates identified in the present study (Dataset C).
(TIF)
S6 Fig. Principal Component Analysis (PCA). PCA of NFD summary data from Table 2.
Autoimmune datasets C and E (green), oral and vaginal carriage datasets D and G (gold), and
larger individual isolate datasets B and F (blue) are included (left), and together with individual
DSTs from data set C identified in the present study (black and numbered by DST).
(TIF)
S1 Table. Primer table. Table of primers used to generate sequence data for C. albicansMLST
typing.
(DOCX)
S2 Table. NFD Summary statistics. Table of NFD summary statistics for individual DSTs
identified in the present study (dataset C) and for datasets B-G. Loss of heterozygosity score is
calculated as (LOHscore) = (hetNFA + homNFP)—(homNFA + homNFP).
(DOCX)
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